Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Apyx MedicalAPYX +0.99%72 Buyback Yield % is 0.00 as of Aug. 18, 2026. GuruFocus rates APYX with a GF Score™ of 72/100 and a GF Value™ of $2.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 341 Medical Devices & Instruments companies, Apyx Medical ranks worse than 293254.84% on this metric.
Buyback yield is the net repurchase of shares outstanding over the market capital of the company. It is a measure of shareholder return.
The historical data trend for Apyx Medical's Buyback Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
APYX vs INGN, QSI, QTRX: Buyback Yield % Comparison
For the Medical Devices subindustry, Apyx Medical's Buyback Yield %, along with its competitors' market caps and Buyback Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Apyx Medical Buyback Yield % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Apyx Medical's Buyback Yield % distribution charts can be found below:
* The bar in red indicates where Apyx Medical's Buyback Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Apyx Medical (APYX) has a Buyback Yield % of 0.00 as of Aug. 18, 2026. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Apyx Medical and its competitors. According to the industry distribution chart, Apyx Medical ranks #999999 out of 341 companies in the Medical Devices & Instruments industry.
Is Apyx Medical's Buyback Yield % too high?
Apyx Medical's current Buyback Yield % is 0.00. Based on the distribution chart, Apyx Medical ranks #999999 out of 341 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Apyx Medical has a GF Score™ of 72/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Apyx Medical's Buyback Yield % compare to INGN and QSI?
According to the Medical Devices & Instruments industry distribution chart, Apyx Medical ranks #999999 out of 341 companies for Buyback Yield %. This places Apyx Medical in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Buyback Yield % for a Medical Devices & Instruments company?
A good Buyback Yield % depends on the Medical Devices & Instruments industry context. However, Buyback Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Buyback Yield % mean?
A high Buyback Yield % can signal that a stock is expensive relative to its fundamentals. Share buyback yield equals the net issuance of stock divided by market cap. View historical data on Apyx Medical and its competitors. Apyx Medical's current Buyback Yield % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Apyx Medical stock overvalued right now?
Based on GuruFocus' analysis, Apyx Medical (APYX) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.21, compared to a current price of $3.06 — trading 38.5% above its estimated fair value. The current Buyback Yield % is 0.00. Apyx Medical's overall GF Score™ is 72/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Buyback Yield % calculated?
Buyback Yield % is calculated from a company's financial statements. For Apyx Medical (APYX), the current Buyback Yield % is 0.00 as of Aug. 18, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Apyx Medical (APYX) Overvalued in 2026?
Based on GuruFocus' analysis, Apyx Medical stock appears to be overvalued.
The current stock price of $3.06 is trading 38.5% above its estimated GF Value™ of $2.21.
GuruFocus considers Apyx Medical to be Significantly Overvalued.
Key valuation signals for APYX:
Buyback Yield %: 0.00
GF Value™: $2.21 vs. price of $3.06 (38.5% above fair value)
No single metric tells the full story. See the APYX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Surgical Aesthetics and Original Equipment Manufacturing (OEM). Its Surgical Aesthetics segment derives the majority of its revenue.
72GF Score
Get the complete analysis for APYX
Buyback Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
APYX has been successfully added to your 
